Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Email Contact Diane Meegan Investor Relations 212-330-8512 Email Contact
A Major Study Compares Direct Blood Volume Measurement Using the BVA-100 With the BNP Test for Managing Fluid Therapy in the Intensive Care Unit
| Source: Daxor Corp.
NEW YORK, NY -- (MARKET WIRE) -- March 5, 2007 -- A study entitled "Does Blood Volume and BNP
Correlate?" was presented at the annual Critical Care Conference in
Orlando. Daxor's (AMEX : DXR ) BVA-100 was used for the study. The senior
authors were Susan M. Apte, Mihae Yu, et al. from Queen's Hospital, Hawaii,
the largest hospital in the Hawaiian Islands. B-type natriuretic peptide
(BNP) is a cardiac neurohormone predominantly released from the ventricles
in response to stretch of ventricular myocytes or increases in wall
tension. BNP is widely used for diagnosing the presence of heart failure.
Values of BNP have been used to guide physicians in determining fluid and
diuretic therapy for patients with cardiac dysfunction. The BNP test is
manufactured by Biosite. The Biosite Company makes no claim that BNP is
a measure of the blood volume status of the patient. However, many
physicians use BNP levels as a guide to administering or withholding fluids
from patients in heart failure.
30 surgical intensive care patients had a total of 58 blood volume
measurements obtained simultaneously with BNP measurements. The diagnosis
of the patients included septic shock, trauma, and hemorrhagic shock. The
study concluded that there was no correlation between BNP levels and the
blood volume status of the patient. This is the largest study reported to
date where blood volumes were actually measured simultaneously with BNP
levels in critically ill patients. The authors concluded that blood volume
measurements may guide in optimizing fluid measurements when there is
uncertainty about the intravascular volume status of complex patients.
This study confirms the clinical impression of a number of physicians that
BNP measurements should not be relied upon as a guide in fluid therapy.
Reliance upon elevated BNP levels as a marker of an expanded blood volume
could theoretically result in the inappropriate withholding of fluid or
blood transfusions in patients with a severely reduced blood volume.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated
Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex,
Daxor's single use diagnostic kit. For more information regarding Daxor
Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website
www.Daxor.com.